


ASX ANNOUNCEMENT**Date of AGM and Closing Date for Director Nominations**

Sydney, 29 September 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held on Thursday, 19 November 2020. The Company will follow the measures in place as set by the Australian and New South Wales governments for the restriction of gatherings and the implementation of social distancing requirements in response to COVID-19.

An item of business at the AGM will be the re-election and appointment of directors. In accordance with clause 13.3 of the Company's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Thursday, 8 October 2020.

Any nominations must be received at the Company's registered office no later than 5:00 pm (Sydney time) on Thursday, 8 October 2020.

ENDS**Actinogen Medical**

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor Enquiries

Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical**About Actinogen Medical**

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from currently available therapies. It works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and particular behavioural symptoms. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in a number of diseases/disorders, including Alzheimer's disease, schizophrenia, diabetes and other conditions associated with cognitive impairment.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, confirmed the drug's strong safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition, which, along with other recently generated data, confirms 11 β -HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment and other symptoms associated with raised cortisol.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2020/21, including MCI due to Alzheimer's disease.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Xanamem™ is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.